Detection of Euglycemic Diabetic Ketoacidosis During Thoracic Surgery 75 Hours After Empagliflozin Discontinuation

Ai Nishida 1, Osamu Ogawa 1,2, Hiroki Takizawa 3,4

Department of Diabetes and Endocrinology, Kameda Medical Center, Kamogawa, JPN 2. Information Management Headquarters, Kameda Medical Center, Kamogawa, JPN 3. Department of Diabetes and Endocrinology, Kameda Medical Center, Kamogawa City, JPN 4. Department of Metabolism and Endocrinology, Juntendo University, Tokyo, JPN

Corresponding author: Ai Nishida, nishida.ai@kameda.jp

Abstract

Euglycemic diabetic ketoacidosis (eDKA) has been increasingly reported as an adverse event of sodium-glucose cotransporter 2 inhibitors (SGLT2i), and the accompanying information on the drug recommends discontinuation three days prior to scheduled surgery. We present a case of a 50-year-old woman who developed eDKA during surgery for a metastatic lung tumor 75 hours after discontinuing SGLT2i. In this case, the onset of eDKA was detected using intraoperative blood gas analysis and urinary ketone measurements. Hence, perioperative eDKA can occur even after three or more days of SGLT2i withdrawal.

Introduction

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are drugs for diabetes treatment that promote urinary glucose excretion. They possess cardioprotective and renoprotective properties. Therefore, they prevent any macro- or microvascular diabetic complications [1,2]. Diabetic ketoacidosis (DKA) is a serious side effect of using SGLT2i. A series of reports of euglycemic DKA (eDKA) with blood glucose levels below 250 mg/dL during SGLT2i use have been published [3]. Perioperative eDKA has also been reported when using SGLT2i [4]. However, there are few reports of eDKA that were diagnosed intraoperatively [5]. We report a case of intraoperatively detected eDKA 75 hours after empagliflozin discontinuation.

This article was previously presented as a meeting abstract at the 664th Kanto Regional Meeting of the Japanese Society of Internal Medicine on November 14, 2020.

Case Presentation

The patient was a 50-year-old woman. She was diagnosed with type 2 diabetes at age 36. Prior to her admission, she was on a drug regimen of vildagliptin 100 mg/day, metformin 1,000 mg/day, miglitol 225 mg/day, empagliflozin 10 mg/day, and multiple insulin injection therapy (insulin glulisine and insulin glargine) with a total daily dose (TDD) of 36 units. She had been prescribed empagliflozin four years prior to admission. No urinary ketones were noted during the outpatient course. Her only other medical history was a total hysterectomy for atypical leiomyosarcoma at age 46. At the time of hysterectomy, the patient was taking empagliflozin until the day before surgery. Oral intake was adequate, and preoperative urine ketones were negative. After stopping empagliflozin on the day of surgery, her urine ketone body test was positive on the third postoperative day with adequate oral intake, but there was no diagnosis of ketoacidosis. Two months prior to her admission, she was diagnosed with a metastatic lung tumor and was scheduled for surgery. One week prior to surgery, she developed chest pain on the right side along with dyspnea. She was admitted to the hospital and diagnosed with a ruptured tumor. On admission, she had no gastrointestinal symptoms. She had generalized fatigue but was conscious. Her body height was 154.9 cm, body weight was 87.7 kg, and BMI was 36.5 kg/m². Her physical examination revealed no abnormal heart sounds, but the breath sounds were better heard in the left lung than in the right lung. No dry skin or skin rash was observed. Her blood test data on admission are shown in Table 1. She had no evidence of acidemia at the time of admission. After admission, she was able to eat 70% of a 1600 kcal/day diet until the day before surgery. In addition, all oral hypoglycemic medications were discontinued, and her blood glucose level remained below 200 mg/dL. The patient’s blood glucose levels were managed with a sliding scale insulin regimen. Her last preoperative insulin dose was 2 units of regular insulin subcutaneously administered 56 hours before the surgery. Her last empagliflozin dose was 72 hours before surgery. On the fourth day of hospitalization, after 15 hours of overnight fasting, the patient underwent right upper lobectomy, thoracic hematoma removal, and axillary lymph node dissection. The pathology result was leiomyosarcoma.
Data | Unit  
--- | ---  
Na | 141 | mEq/L  
K | 4.5 | mEq/L  
Cl | 110 | mEq/L  
BUN | 13 | mg/dL  
Creatinine | 0.39 | mEq/L  
AST | 12 | IU/L  
ALT | 19 | IU/L  
Alb | 3.3 | g/dL  
CRP | 2.13 | mg/dL  
WBC | 179 | ×10⁹/µL  
RBC | 422 | ×10⁹/µL  
Hb | 12.8 | g/dL  
Plt | 26.8 | ×10⁹/µL  
Hemoglobin A1c | 9.2 | %  
BGA  
ph | 7.372  
PCO₂ | 35.2 | Torr  
PO₂ | 68.1 | Torr  
HCO₃⁻ | 20 | mmol/L  
BE | -4.5 | mmol/L  
Glucose | 229 | mg/dL  
Lactate | 1.3 | mmol/L  

**TABLE 1: Laboratory data at admission**  
Na, sodium; K, potassium; Cl, chloride; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Alb, albumin; CRP, C-reactive protein; WBC, white blood cell count; RBC, red blood cell count; Hb, hemoglobin; Plt, platelet; BGA, blood gas data analysis; PaCO₂, partial pressure of carbon dioxide; PaO₂, partial pressure of oxide; HCO₃⁻, bicarbonate ion; BE, base excess

She was started on an intravenous infusion of sodium L-lactate Ringer’s solution without insulin and carbohydrate from 2 hours before surgery. She had an intraoperative blood glucose level of 159 mg/dL but showed metabolic acidosis. When the metabolic acidosis did not improve, a urinary ketone test was performed, which showed a value of 3+.

She was diagnosed with eDKA and started on continuous intravenous insulin. Insulin infusion was continued postoperatively. The course of blood gas analysis (BGA) is shown in Table 2. Four and a half hours after the surgery, the acidosis improved to reach pH 7.367. She had no gastrointestinal symptoms after waking up from anesthesia.
She was started on food the day after surgery, and her insulin injections were changed from intravenous to subcutaneous. She was discharged on the 14th postoperative day. Two days prior to discharge, she resumed SGLT2i, and her discharge prescription was empagliflozin 10 mg and insulin multiple injection therapy (insulin glulisine and insulin glargine) with a TDD of 38 units. Her pre-discharge testing was negative for glutamic acid decarboxylase antibodies, and her urine ketones were negative 12 days after the discharge.

**Discussion**

Two clinical findings are highlighted in this study. First, intraoperative eDKA can occur even after 75 hours of empagliflozin discontinuation. Second, intraoperative measurement of ketones and BGA is useful for the early detection of eDKA. These findings are elaborated on further below.

**Perioperative eDKA occurrence after 75 hours of empagliflozin discontinuation**

eDKA has traditionally been reported as an adverse event of SGLT2i [6,7]. In addition, perioperative SGLT2i-related DKA has been reported [4,8-13]. There are reports of intraoperative eDKA diagnosed 28 hours after empagliflozin discontinuation [5]. It is therefore recommended that SGLT2i be discontinued three to four days prior to surgery [14,15]. The U.S. Food and Drug Administration has revised the package insert to discontinue canagliflozin, dapagliflozin, and empagliflozin three days before scheduled surgery on March 15, 2022 [16].

In this case, eDKA was diagnosed intraoperatively 75 hours after empagliflozin discontinuation. It should be noted that DKA may occur even after a sufficient withdrawal period. Several triggers of SGLT2i-related DKA have been identified [17]. According to the review, surgical stress, insufficient pre-/post-operative or reduced dose of insulin, reduced perioperative oral intake, infection, malignancy, dehydration, and

**TABLE 2: Laboratory testing perioperative phase and clinical course**

|                       | At the end of surgery | ICU admission |
|-----------------------|-----------------------|--------------|
| pH                    | 7.303                 | 7.216        |
| PaCO₂ (mmHg)         | 33.8                  | 37.8         |
| PaO₂ (mmHg)          | 41.9                  | 151          |
| HCO₃⁻ (mmol/L)       | 16.4                  | 15           |
| BE (mmol/L)          | -9                    | -11.9        |
| Na (mmol/L)          | 136                   | 140          |
| K (mmol/L)           | 3.6                   | 4.1          |
| CL (mmol/L)          | 103                   | 106          |
| Lactate (mmol/L)     | 0.8                   | 1            |
| Glucose (mg/dL)      | 151                   | 192          |

Urine ketone positive

Start insulin infusion

2022 Nishida et al. Cureus 14(10): e29974. DOI 10.7759/cureus.29974
decreased oral intake are some known triggers [17]. In this case, the triggers were lower insulin dosage, lower oral intake than before admission, inflammatory response, presence of malignancy, and surgical stress. Based on the above, we assume that the patient had SGLT2i-associated eDKA due to a combination of triggers, including decreased insulin dosage, decreased oral intake, inflammatory response, presence of malignancy, and surgical stress. The patient had a previous history of positive urine ketones in the perioperative period. This case could have been prone to ketosis due to some triggers even after discontinuation of SGLT2i. Therefore, eDKA may have occurred even after 75 hours of the last empagliflozin administration. Even if blood glucose levels were not high, preoperative intravenous infusion with glucose and insulin could have facilitated the prevention of SGLT2i-related eDKA.

It is useful to measure ketones and BGA during surgery for early detection of intraoperative eDKA

Diagnosis of intraoperative DKA is difficult because many symptoms of DKA are nonspecific; in addition, it is difficult to identify symptoms while the patient is under the influence of general anesthesia [11]. Furthermore, as in this case, DKA can occur even when the recommended withdrawal period is followed. Several proposals have been made for identifying and managing SGLT2i-associated DKA [17]. Among them, checking for the presence of ketones and BGA is primary. These measurements may be useful for the early detection of DKA and prevention of exacerbations.

The sodium nitroprusside-based test for urine "ketones" has a low threshold of detection for acetocetate, is relatively insensitive to acetone, and fails to detect β-hydroxybutyrate [18]. Therefore, measurement of urinary ketones is not appropriate for early detection of complete DKA, and measurement of blood ketones using point-of-care-testing is preferred when possible.

This case was diagnosed with DKA intraoperatively. There was no preoperative acidosis, and ketosis was not considered. The possibility that preoperative ketosis was present cannot be ruled out. It is also possible that the addition of surgical stress may have led to DKA. Therefore, medical professionals should conduct perioperative measurements of blood ketone bodies and BGA.

Conclusions

There are several ways to prevent SGLT2i-related eDKA in the perioperative period. Discontinuation of SGLT2i three to four days before surgery is one such way. However, it has been shown that intraoperative eDKA can occur even after empagliflozin has been discontinued for more than three days. Perioperative measurement of ketones and BGA, three days after discontinuation of SGLT2i, is useful for the prevention and early detection of intraoperative eDKA.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services Info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, Pugidhipati NJ: Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: [ACC guideline comparison]. J Am Coll Cardiol. 2022, 79:1849-57. 10.1016/j.jacc.2022.02.046
2. Bailey CJ, Day C, Bellary S: Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022, 22:59-52. 10.1007/s11892-021-01442-z
3. Fralick M, Schneeweiss S, Patorno E: Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017, 376:2300-2. 10.1056/NEJMc1701990
4. Smith A, Holtrop J, Sadoun M: Post-operative euglycemic diabetic ketoacidosis in a patient with SGLT-2 inhibitor use and recent sleeve gastrectomy. Cureus. 2021, 13:e14297. 10.7759/cureus.14297
5. Kitahara C, Morita S, Kishimoto S, et al.: Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: a case report. J Diabetes Investig. 2021, 12:664-7. 10.1111/jdi.13565
6. Peters AL, Buschar EJ, Buse JB, Cohan P, Diner JC, Hirsch IB: Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibitor. Diabetes Care. 2015, 38:1687-93. 10.2337/dc15-0843
7. Goldberg RM, Berard LD, Cheng AV, Gilbert JD, Verma S, Woo VC, Yale JF: SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-2664.e1. 10.1016/j.clinthera.2016.11.002
8. Lau A, Bruce S, Wang E, Ree R, Rondi K, Chau A: Perioperative implications of sodium-glucose
cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery. Can J Anaesth. 2018, 65:188-95. 10.1007/s12630-017-1018-6
9. Jhaveri U, Vardesh D: Sodium-glucose cotransporter-2 inhibitors and euglycaemic diabetic ketoacidosis in the perioperative period: case report. Cureus. 2019, 11:e5455. 10.7759/cureus.5455
10. Breich F, Daberg H, Kapoor A, Charbek E, Kamel G: Post-surgical euglycemic diabetic ketoacidosis in a patient on empagliflozin in the intensive care unit. Cureus. 2019, 11:e4496. 10.7759/cureus.4496
11. Thiruvenskararaj V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D: Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019, 123:27-36. 10.1016/j.bja.2019.03.028
12. Kapila V, Topf J: Sodium-glucose co-transporter 2 inhibitor–associated euglycemic diabetic ketoacidosis after bariatric surgery: a case and literature review. Cureus. 2021, 13:e17093. 10.7759/cureus.17093
13. Chandrakumar HP, Chillumuntala S, Singh G, McFarlane SI: Postoperative euglycemic ketoacidosis in type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitor: insights into pathogenesis and management strategy. Cureus. 2021, 13:e15533. 10.7759/cureus.15533
14. Draznin B, Aroda VR, Bakris G, et al.: 16. Diabetes care in the hospital: standards of medical care in diabetes-2022. Diabetes Care. 2022, 45:S244-53. 10.2337/dc22-S016
15. Madhok J, Vanneman MW: SGLT-2 inhibitors: proliferating indications and perioperative pitfalls. J Cardiothorac Vasc Anesth. 2022, 56:1815–9. 10.1053/j.jvca.2022.02.019
16. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2022). Accessed: May 23, 2022: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings...
17. Fleming N, Hamblin PS, Story D, Ekinici EI: Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose cotransporter 2 inhibitors. J Clin Endocrinol Metab. 2020, 105: 10.1210/clinem/dgaa200
18. Riley RS, McPherson RA: Basic examination of urine. Henry’s Clinical Diagnosis and Management by Laboratory Methods. 24th Edition. McPherson RA, Pincus MR (ed): Elsevier BV, Amsterdam; 2021. 468–509.